{"nct_id":"NCT02252263","title":"A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma","status":"COMPLETED","status_verified_date":"2017-10","start_date":"2014-12-09","start_date_type":"ACTUAL","primary_completion_date":"2017-10-10","primary_completion_date_type":"ACTUAL","completion_date":"2017-10-10","completion_date_type":"ACTUAL","phases":["PHASE1"],"tickers":["BMY"]}